CN104768970B - 模拟肽 - Google Patents

模拟肽 Download PDF

Info

Publication number
CN104768970B
CN104768970B CN201380057907.5A CN201380057907A CN104768970B CN 104768970 B CN104768970 B CN 104768970B CN 201380057907 A CN201380057907 A CN 201380057907A CN 104768970 B CN104768970 B CN 104768970B
Authority
CN
China
Prior art keywords
seq
amino acid
apoa
site
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380057907.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104768970A (zh
Inventor
尼古拉斯·威勒米尔
塞布丽娜·派格诺
奥利弗·哈特莱
休伯特·格特内
普利斯希拉·凯梅洛特谢拉
保罗·卡特勒
菲利普·费伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
University of Geneva
Original Assignee
F Hoffmann La Roche AG
University of Geneva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, University of Geneva filed Critical F Hoffmann La Roche AG
Publication of CN104768970A publication Critical patent/CN104768970A/zh
Application granted granted Critical
Publication of CN104768970B publication Critical patent/CN104768970B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
CN201380057907.5A 2012-11-06 2013-11-06 模拟肽 Expired - Fee Related CN104768970B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12191474 2012-11-06
EP12191474.1 2012-11-06
PCT/IB2013/059948 WO2014072916A1 (en) 2012-11-06 2013-11-06 Mimetic peptides

Publications (2)

Publication Number Publication Date
CN104768970A CN104768970A (zh) 2015-07-08
CN104768970B true CN104768970B (zh) 2019-11-15

Family

ID=47115623

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380057907.5A Expired - Fee Related CN104768970B (zh) 2012-11-06 2013-11-06 模拟肽

Country Status (11)

Country Link
US (1) US10087234B2 (enExample)
EP (1) EP2917234B1 (enExample)
JP (1) JP6499967B2 (enExample)
KR (1) KR102215175B1 (enExample)
CN (1) CN104768970B (enExample)
BR (1) BR112015010276A2 (enExample)
CA (1) CA2888657C (enExample)
ES (1) ES2859559T3 (enExample)
MX (1) MX364626B (enExample)
RU (1) RU2662973C2 (enExample)
WO (1) WO2014072916A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018210404B2 (en) * 2017-01-19 2022-01-27 Novo Nordisk A/S ApoC-II mimetic peptides
SG11202010016QA (en) * 2018-04-10 2020-11-27 Sanofi Aventis Deutschland Lixisenatide synthesis with capping
MX2020010716A (es) 2018-04-10 2021-03-09 Sanofi Aventis Deutschland Metodo para escindir de la fase solida peptidos unidos a una fase solida.
CN108948158B (zh) * 2018-07-21 2021-06-15 河南大学 四连接素模拟肽tnp及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008156873A2 (en) * 2007-06-20 2008-12-24 Merck & Co., Inc. Apoa-1 peptide mimetics
WO2012149563A1 (en) * 2011-04-29 2012-11-01 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
EP1706131A4 (en) 2003-12-15 2009-08-12 Univ California THE CELLULAR CHOLESTEROL EFFLUX STIMULATING HELICULAR SYNTHETIC PEPTIDES
WO2007022248A2 (en) * 2005-08-16 2007-02-22 Sloan Kettering Institute For Cancer Research Methods of detection of cancer using peptide profiles
WO2012040459A2 (en) * 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008156873A2 (en) * 2007-06-20 2008-12-24 Merck & Co., Inc. Apoa-1 peptide mimetics
WO2012149563A1 (en) * 2011-04-29 2012-11-01 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents

Also Published As

Publication number Publication date
WO2014072916A1 (en) 2014-05-15
KR20150082350A (ko) 2015-07-15
MX2015005761A (es) 2015-08-12
US10087234B2 (en) 2018-10-02
CA2888657C (en) 2022-05-03
US20150291682A1 (en) 2015-10-15
RU2662973C2 (ru) 2018-07-31
ES2859559T3 (es) 2021-10-04
MX364626B (es) 2019-05-03
RU2015121688A (ru) 2016-12-27
JP2016505514A (ja) 2016-02-25
EP2917234A1 (en) 2015-09-16
CN104768970A (zh) 2015-07-08
EP2917234B1 (en) 2020-12-02
KR102215175B1 (ko) 2021-02-15
BR112015010276A2 (pt) 2019-10-15
CA2888657A1 (en) 2014-05-15
JP6499967B2 (ja) 2019-04-10

Similar Documents

Publication Publication Date Title
US20250123275A1 (en) Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use
TWI918577B (zh) 雙重澱粉素及降鈣素受體促效劑及其用途
US20070031416A1 (en) Use of antibody
US10087234B2 (en) Mimetic peptides
CN116917312A (zh) 长效胰淀素受体激动剂及其用途
JP2003523167A (ja) 炎症疾患の治療
Fu et al. Characterization of anti‐peptide antibodies directed against an extracellular immunogenic epitope on the human α1‐adrenergic receptor
WO2003006603A2 (en) Triple polypeptide complexes
CN119912552A (zh) 一种血管紧张素ii-1型受体多肽或融合物及其应用
Beaino et al. Thiopalmitoylated peptides from the peripheral nervous system myelin p0 protein: synthesis, characterization, and neuritogenic properties
JPH06157592A (ja) ペプチドもしくはその誘導体、それらとタンパク質との結合体、及びこれらを免疫源とする抗エンドセリン−１抗体の製造方法
JP4557421B2 (ja) 自己免疫疾患を治療するためのフィラグリン由来シトルリンペプチドの使用
CN1403819A (zh) 抗α－胞衬蛋白多肽抗体测定在干燥综合征诊断中的应用
KR101156992B1 (ko) 혈압 강하 활성을 가지는 펩티드
WO2001004298A1 (fr) Nouvelle substance physiologiquement active, procede de production et utilisation
JP3024987B2 (ja) 抗体、その製造法および用途
US20060051344A1 (en) Antibody and utilization of the same
JP2004159654A (ja) 抗体およびその用途
JP2006180704A (ja) 新規タンパクおよびその用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20191115

CF01 Termination of patent right due to non-payment of annual fee